Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 26;11(5):ofae223.
doi: 10.1093/ofid/ofae223. eCollection 2024 May.

Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS)

Jade Couchepin  1 , Ilana Reinhold  2 , Ilona Kronig  3 , Monia Guidi  4   5   6 , Thierry Buclin  4 , Peter W Schreiber  2 , Dionysios Neofytos  3 , Frederic Lamoth  1   7 ; Fungal Infection Network of Switzerland (FUNGINOS)
Collaborators, Affiliations

Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS)

Jade Couchepin et al. Open Forum Infect Dis. .

Abstract

This analysis of 116 isavuconazole therapy courses shows that hepatic test disturbances (HTDs) were relatively frequent (29% of cases) but rarely led to treatment interruption (5%). Importantly, patients with baseline HTDs, including those attributed to a first-line triazole, did not exhibit a higher risk of subsequent HTD under isavuconazole therapy.

Keywords: aspergillosis; hepatotoxicity; liver; mucormycosis; triazoles.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. Outside the submitted work: F. L. received research funding from Gilead, MSD, and Novartis and speaker honoraria from Pfizer, Gilead, MSD, Mundipharma, and Becton-Dickinson. All contracts were made with and fees paid to his institution. P. W. S. received travel grants from Pfizer and Gilead, speaker honorary from Pfizer, and fees for advisory board activity from Pfizer and Gilead. All other authors report no potential conflicts.

References

    1. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis 2010; 50:1091–100. - PubMed
    1. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101–11. - PubMed
    1. Lamoth F, Calandra T. Pulmonary aspergillosis: diagnosis and treatment. Eur Respir Rev 2022; 31:220114. - PMC - PubMed
    1. Lamoth F, Kontoyiannis DP. Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients. Antimicrob Agents Chemother 2019; 63:e01244-19. - PMC - PubMed
    1. Lass-Flörl C. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs 2011; 71:2405–19. - PubMed